Luwen Wang1, Mengyu Liu2, Ju Gao1, Amber M Smith2, Hisashi Fujioka3, Jingjing Liang2, George Perry4, Xinglong Wang1,2. 1. Department of Pharmacology and Experimental Neurosciences, University of Nebraska Medical Centre, Omaha, NE, USA. 2. Department of Pathology, Case Western Reserve University, Cleveland, OH, USA. 3. Electron Microscopy Core Facility, Case Western Reserve University, Cleveland, OH, USA. 4. College of Sciences, University of Texas at San Antonio, San Antonio, TX, USA.
Abstract
BACKGROUND: Abnormalities of mitochondrial fission and fusion, dynamic processes known to be essential for various aspects of mitochondrial function, have repeatedly been reported to be altered in Alzheimer's disease (AD). Neurofibrillary tangles are known as a hallmark feature of AD and are commonly considered a likely cause of neurodegeneration in this devastating disease. OBJECTIVE: To understand the pathological role of mitochondrial dynamics in the context of tauopathy. METHODS: The widely used P301S transgenic mice of tauopathy (P301S mice) were crossed with transgenic TMFN mice with the forced expression of Mfn2 specifically in neurons to obtain double transgenic P301S/TMFN mice. Brain tissues from 11-month-old non-transgenic (NTG), TMFN, P301S, and P301S/TMFN mice were analyzed by electron microscopy, confocal microscopy, immunoblot, histological staining, and immunostaining for mitochondria, tau pathology, and tau pathology-induced neurodegeneration and gliosis. The cognitive function was assessed by the Barnes maze. RESULTS: P301S mice exhibited mitochondrial fragmentation and a consistent decrease in Mfn2 compared to age-matched NTG mice. When P301S mice were crossed with TMFN mice (P301S/TMFN mice), neuronal loss, as well as mitochondria fragmentation were significantly attenuated. Greatly alleviated tau hyperphosphorylation, filamentous aggregates, and thioflavin-S positive tangles were also noted in P301S/TMFN mice. Furthermore, P301S/TMFN mice showed marked suppression of neuroinflammation and improved cognitive performance in contrast to P301S mice. CONCLUSION: These in vivo findings suggest that promoted mitochondrial fusion suppresses toxic tau accumulation and associated neurodegeneration, which may protect against the progression of AD and related tauopathies.
BACKGROUND: Abnormalities of mitochondrial fission and fusion, dynamic processes known to be essential for various aspects of mitochondrial function, have repeatedly been reported to be altered in Alzheimer's disease (AD). Neurofibrillary tangles are known as a hallmark feature of AD and are commonly considered a likely cause of neurodegeneration in this devastating disease. OBJECTIVE: To understand the pathological role of mitochondrial dynamics in the context of tauopathy. METHODS: The widely used P301S transgenic mice of tauopathy (P301S mice) were crossed with transgenic TMFN mice with the forced expression of Mfn2 specifically in neurons to obtain double transgenic P301S/TMFN mice. Brain tissues from 11-month-old non-transgenic (NTG), TMFN, P301S, and P301S/TMFN mice were analyzed by electron microscopy, confocal microscopy, immunoblot, histological staining, and immunostaining for mitochondria, tau pathology, and tau pathology-induced neurodegeneration and gliosis. The cognitive function was assessed by the Barnes maze. RESULTS: P301S mice exhibited mitochondrial fragmentation and a consistent decrease in Mfn2 compared to age-matched NTG mice. When P301S mice were crossed with TMFN mice (P301S/TMFN mice), neuronal loss, as well as mitochondria fragmentation were significantly attenuated. Greatly alleviated tau hyperphosphorylation, filamentous aggregates, and thioflavin-S positive tangles were also noted in P301S/TMFN mice. Furthermore, P301S/TMFN mice showed marked suppression of neuroinflammation and improved cognitive performance in contrast to P301S mice. CONCLUSION: These in vivo findings suggest that promoted mitochondrial fusion suppresses toxic tau accumulation and associated neurodegeneration, which may protect against the progression of AD and related tauopathies.
Authors: Dale W Hailey; Angelika S Rambold; Prasanna Satpute-Krishnan; Kasturi Mitra; Rachid Sougrat; Peter K Kim; Jennifer Lippincott-Schwartz Journal: Cell Date: 2010-05-14 Impact factor: 41.582
Authors: David Sebastián; María Isabel Hernández-Alvarez; Jessica Segalés; Eleonora Sorianello; Juan Pablo Muñoz; David Sala; Aurélie Waget; Marc Liesa; José C Paz; Peddinti Gopalacharyulu; Matej Orešič; Sara Pich; Rémy Burcelin; Manuel Palacín; Antonio Zorzano Journal: Proc Natl Acad Sci U S A Date: 2012-03-16 Impact factor: 11.205
Authors: Katherine J Kopeikina; George A Carlson; Rose Pitstick; Adam E Ludvigson; Alan Peters; Jennifer I Luebke; Robert M Koffie; Matthew P Frosch; Bradley T Hyman; Tara L Spires-Jones Journal: Am J Pathol Date: 2011-08-18 Impact factor: 4.307
Authors: Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2012-05 Impact factor: 3.685
Authors: Gian-Luca McLelland; Thomas Goiran; Wei Yi; Geneviève Dorval; Carol X Chen; Nadine D Lauinger; Andrea I Krahn; Sepideh Valimehr; Aleksandar Rakovic; Isabelle Rouiller; Thomas M Durcan; Jean-François Trempe; Edward A Fon Journal: Elife Date: 2018-04-20 Impact factor: 8.140
Authors: Teresa Rodríguez-Martín; Amy M Pooler; Dawn H W Lau; Gábor M Mórotz; Kurt J De Vos; Jonathan Gilley; Michael P Coleman; Diane P Hanger Journal: Neurobiol Dis Date: 2015-10-11 Impact factor: 5.996